Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + gemcitabine + liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A triplet chemotherapy regimen combining docetaxel (a taxane that inhibits cell division by binding to microtubules), gemcitabine (a nucleoside analog that interferes with DNA synthesis), and liposomal doxorubicin (an anthracycline encapsulated in liposomes). This combination has been investigated for treatment of various cancers including advanced breast cancer and has shown promising activity with a manageable toxicity profile.
02
Targets
MicrotubuleDNA polymerase familyTOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on docetaxel + gemcitabine + liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + gemcitabine + liposomal doxorubicin.